Skip to main navigation Skip to search Skip to main content

Mouse-Human Chimeric Antibody against the Multidrug Transporter P-Glycoprotein1

  • Hirofumi Hamada
  • , Keiko Ariyoshi
  • , Yuji Heike
  • , Shigeo Sato
  • , Keiji Miura
  • , Kohzoh Kameyama
  • , Yoshikazu Kurosawa
  • , Takashi Tsuruo

Research output: Contribution to journal › Article › peer-review

Abstract

In an effort to devise an effective treatment for human drug-resistant cancers, we have generated a monoclonal antibody, MRK16, reactive to the multidrug transporter P-glycoprotein. The monoclonal antibody inhibited the growth of human drug-resistant tumor cells in a xenograft model, suggesting its potential usefulness in the immunotherapy of drug-resistant cancers. In this study, we have developed a recombinant chimeric antibody in which the antigen-recognizing variable regions of MRK16 are joined with the constant regions of human antibodies. When human effector cells were used, the chimeric antibody, MH162, was more effective in killing drug-resistant tumor cells than the all-mouse monoclonal MRK16. The chimeric antibody against the multidrug transporter P-glycoprotein will be a useful agent in immunotherapy of human drug-resistant cancers.

Original languageEnglish
Pages (from-to)3167-3171
Number of pages5
JournalCancer Research
Volume50
Issue number11
Publication statusPublished - 01-06-1990

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Mouse-Human Chimeric Antibody against the Multidrug Transporter P-Glycoprotein1'. Together they form a unique fingerprint.

Cite this